Matteo Bassetti1, Garyphallia Poulakou2, Etienne Ruppe3, Emilio Bouza4,5,6,7, Sebastian J Van Hal8, Adrian Brink9,10. 1. Department of Medicine, Infectious Diseases Clinic, University of Udine and Azienda Sanitaria Universitaria Integrata, Piazzale S. Maria Della Misericordia 15, 33100, Udine, Italy. mattba@tin.it. 2. Fourth Department of Internal Medicine, School of Medicine, Attikon University General Hospital, Athens National and Kapodistrian University, 1 Rimini St, 12462, Athens, Greece. 3. Genomic Research Laboratory, Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 4. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 5. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 6. Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. 7. CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain. 8. Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 9. Ampath National Laboratory Services, Department of Clinical Microbiology, Milpark Hospital, Johannesburg, South Africa. 10. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Abstract
PURPOSE: To describe the current standards of care and major recent advances with regard to antimicrobial resistance (AMR) and to give a prospective overview for the next 30 years in this field. METHODS: Review of medical literature and expert opinion were used in the development of this review. RESULTS: There is undoubtedly a large clinical and public health burden associated with AMR in ICU, but it is challenging to quantify the associated excess morbidity and mortality. In the last decade, antibiotic stewardship and infection prevention and control have been unable to prevent the rapid spread of resistant Gram-negative bacteria (GNB), in particular carbapenem-resistant Pseudomonas aeruginosa (and other non-fermenting GNB), extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae (CRE). The situation appears more optimistic currently for Gram-positive, where Staphylococcus aureus, and particularly methicillin-resistant S. aureus (MRSA), remains a cardinal cause of healthcare-associated infections worldwide. Recent advancements in laboratory techniques allow for a rapid identification of the infecting pathogen and antibiotic susceptibility testing. Their impact can be particularly relevant in settings with prevalence of MDR, since they may guide fine-tuning of empirically selected regimen, facilitate de-escalation of unnecessary antimicrobials, and support infection control decisions. Currently, antibiotics are the primary anti-infective solution for patients with known or suspected MDR bacteria in intensive care. Numerous incentives have been provided to encourage researchers to work on alternative strategies to reverse this trend and to provide a means to treat these pathogens. Although some promising antibiotics currently in phase 2 and 3 of development will soon be licensed and utilized in ICU, the continuous development of an alternative generation of compounds is extremely important. There are currently several promising avenues available to fight antibiotic resistance, such as faecal microbiota, and phage therapy.
PURPOSE: To describe the current standards of care and major recent advances with regard to antimicrobial resistance (AMR) and to give a prospective overview for the next 30 years in this field. METHODS: Review of medical literature and expert opinion were used in the development of this review. RESULTS: There is undoubtedly a large clinical and public health burden associated with AMR in ICU, but it is challenging to quantify the associated excess morbidity and mortality. In the last decade, antibiotic stewardship and infection prevention and control have been unable to prevent the rapid spread of resistant Gram-negative bacteria (GNB), in particular carbapenem-resistant Pseudomonas aeruginosa (and other non-fermenting GNB), extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae (CRE). The situation appears more optimistic currently for Gram-positive, where Staphylococcus aureus, and particularly methicillin-resistant S. aureus (MRSA), remains a cardinal cause of healthcare-associated infections worldwide. Recent advancements in laboratory techniques allow for a rapid identification of the infecting pathogen and antibiotic susceptibility testing. Their impact can be particularly relevant in settings with prevalence of MDR, since they may guide fine-tuning of empirically selected regimen, facilitate de-escalation of unnecessary antimicrobials, and support infection control decisions. Currently, antibiotics are the primary anti-infective solution for patients with known or suspected MDR bacteria in intensive care. Numerous incentives have been provided to encourage researchers to work on alternative strategies to reverse this trend and to provide a means to treat these pathogens. Although some promising antibiotics currently in phase 2 and 3 of development will soon be licensed and utilized in ICU, the continuous development of an alternative generation of compounds is extremely important. There are currently several promising avenues available to fight antibiotic resistance, such as faecal microbiota, and phage therapy.
Authors: S Newitt; P R Myles; J A Birkin; V Maskell; R C B Slack; J S Nguyen-Van-Tam; L Szatkowski Journal: J Hosp Infect Date: 2015-01-15 Impact factor: 3.926
Authors: Bruce Y Lee; Sarah M Bartsch; Kim F Wong; James A McKinnell; Rachel B Slayton; Loren G Miller; Chenghua Cao; Diane S Kim; Alexander J Kallen; John A Jernigan; Susan S Huang Journal: Am J Epidemiol Date: 2016-02-08 Impact factor: 4.897
Authors: D O Andrey; P François; C Manzano; E J Bonetti; S Harbarth; J Schrenzel; W L Kelley; A Renzoni Journal: Eur J Clin Microbiol Infect Dis Date: 2016-10-15 Impact factor: 3.267
Authors: Boun Kim Tan; Emmanuel Vivier; Karim Ait Bouziad; Jean-Ralph Zahar; Christian Pommier; Laurence Parmeland; Caroline Pariset; Pauline Misslin; Catherine Haond; Philippe Poirié; Laura Temime; Mounia N Hocine Journal: Intensive Care Med Date: 2018-02-02 Impact factor: 17.440
Authors: Jan J De Waele; Murat Akova; Massimo Antonelli; Rafael Canton; Jean Carlet; Daniel De Backer; George Dimopoulos; José Garnacho-Montero; Jozef Kesecioglu; Jeffrey Lipman; Mervyn Mer; José-Artur Paiva; Mario Poljak; Jason A Roberts; Jesus Rodriguez Bano; Jean-François Timsit; Jean-Ralph Zahar; Matteo Bassetti Journal: Intensive Care Med Date: 2017-12-29 Impact factor: 17.440
Authors: Randi Marie Mohus; Julie Paulsen; Lise Gustad; Åsa Askim; Arne Mehl; Andrew T DeWan; Jan Egil Afset; Bjørn Olav Åsvold; Erik Solligård; Jan Kristian Damås Journal: Intensive Care Med Date: 2018-07-23 Impact factor: 17.440